GlassScriptPhysician profile
Craig Joseph Cender
NPI 1073502068
$2,198.77
in general payments reported to CMS, 2019-2025
22 companies · $743 in 2025
The $743 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $110 · 2022: $31.81 · 2023: $324 · 2024: $727 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,793.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $393.59 | 2022-2025 | Skyrizi, Linzess, Viberzi |
| Janssen Biotech, INC. | $333.35 | 2024-2025 | Tremfya, Stelara |
| Covidien LP | $280.65 | 2019-2020 | |
| Steris Corporation | $205.93 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $188.49 | 2024-2025 | Entyvio |
| Olympus America INC. | $177.09 | 2023-2024 | Endocuff Vision, Visiglide, Single Use Aspiration Needle Na-U200h |
| Ironwood Pharmaceuticals, INC | $81.73 | 2022-2024 | Linzess |
| Merck Sharp & Dohme LLC | $66.74 | 2019 | |
| Intercept Pharmaceuticals, INC. | $65.44 | 2023-2025 | Ocaliva |
| Pentax of America, INC. | $58.60 | 2025 | Pentax Medical, C2 Cryoballoon Focal Controller, C2 Cryoballoon |
| Pfizer INC. | $55.72 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $49.28 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.04 | 2023-2024 | Trulance, Xifaxan |
| Ipsen Biopharmaceuticals, INC | $31.62 | 2025 | Iqirvo |
| Qol Medical, LLC | $30.54 | 2025 | Sucraid |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $26.49 | 2024 | Resmetirom |
| Laborie Medical Technologies Corp. | $26.44 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $23.89 | 2025 | Dupixent |
| Boston Scientific Corporation | $23.34 | 2025 | Cre Pro |
| Siemens Medical Solutions USA, INC. | $21.15 | 2025 | Cios Spin |
| Genzyme Corporation | $13.31 | 2023 | |
| Travere Therapeutics, INC. | $2.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Cender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.